Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker (Review)

Experimental and Therapeutic Medicine

Volumn 2, Issue 3, 2011, Pages 385-391

  Ren, Chuanli ^a   Han, Chongxu ^a   Wang, Daxin ^a   Zhao, Xiaohang ^b   Jin, Guangfu ^c   Shen, Hongbing ^c  

^a CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Circulating tumor cells; Epithelial mesenchymal transition; Prognosis; Solid tumors

Indexed keywords

TUMOR MARKER;

CANCER CELL; CANCER STEM CELL; CELL SEPARATION; CIRCULATING TUMOR CELL; HUMAN; METASTASIS; NONHUMAN; PROGNOSIS; REVIEW; SOLID TUMOR; SYSTEMIC CIRCULATION;

EID: 79953284724     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.234     Document Type: Review

References (86)

1. Maheswaran S and Haber DA: Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 20: 96-99, 2010.
2. Pantel K, Alix-panabieres C and Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol 6: 339-351, 2009.
3. Pantel K, Brakenhoff RH and Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8: 329-340, 2008.
4. Ashworth A: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14: 146-149, 1869.
5. Mocellin S, Keilholz U, Rossi CR and Nitti D: Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med 12: 130-139, 2006.
6. Peach G, Kim C, Zacharakis E, Purkayastha S and Ziprin P Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J cancer 102: 1327-1334, 2010.
7. Alunni-Fabbroni M and Sandri MT: Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 50: 289-297, 2010.
8. Allan AL and Keeney M: Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010: 426218, 2010.
9. Panteleakou Z, Lembessis P, Sourla A, et al: Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 15: 101-114, 2009.
10. Dotan E, Cohen SJ, Alpaugh KR and Meropol NJ: Circulating tumor cells: evolving evidence and future challenges. Oncologist 14: 1070-1082, 2009.
11. Ring A, Smith IE and Dowsett M: Circulating tumour cells in breast cancer. Lancet Oncol 5: 79-88, 2004.
12. Nagrath S, Sequist LV, Maheswaran S, et al: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450: 1235-1239, 2007.
13. Sequist LV, Nagrath S, Toner M, Haber DA and Lynch TJ: The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 4: 281-283, 2009.
14. Cristofanilli M: The biological information obtainable from circulating tumor cells. Breast 18 (Suppl 3): 38-40, 2009.
15. Botteri E, Sandri MT, Bagnardi V, et al: Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat 122: 211-217, 2010.
16. Nole F, Munzone E, Zorzino L, et al: Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 19: 891-897, 2008.
17. Apostolaki S, Perraki M, Pallis A, et al: Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 18: 851-858, 2007.
18. Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J clin Oncol 23: 1420-1430, 2005.
19. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791, 2004.
20. Takeuchi H and Kitagawa Y: Circulating tumor cells in gastrointestinal cancer. J Hepatobiliary Pancreat Surg 17: 577-582, 2010.
21. Xenidis N, Ignatiadis M, Apostolaki S, et al: Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27: 2177-2184, 2009.
22. Wu C, Hao H, Li L, et al: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 4: 30-36, 2009.
23. Wong SC, Chan CM, Ma BB, et al: Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 15: 1005-1012, 2009.
24. Scher HI, Jia X, de Bono JS, et al: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10: 233-239, 2009.
25. Stakenborg T, Liu C, Henry O, et al: Automated genotyping of circulating tumor cells. Expert Rev Mol Diagn 10: 723-729, 2010.
26. Luzzi KJ, MacDonald IC, Schmidt EE, et al: Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153: 865-873, 1998.
27. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK and Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97: 14608-14613, 2000.
28. Shaffer DR, Leversha MA, Danila DC, et al: Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13: 2023-2029, 2007.
29. Fehm T, Sagalowsky A, Clifford E, et al: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8: 2073-2084, 2002.
30. Husemann Y, Geigl JB, Schubert F, et al: Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68, 2008.
31. Meng S, Tripathy D, Frenkel EP, et al: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10: 8152-8162, 2004.
32. Kallergi G, Mavroudis D, Georgoulias V and Stournaras C: Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13: 79-88, 2007.
33. Kallergi X, Kallergi G, Agelaki S, et al: Phosphorylated EGFR and PI-3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 10: R80, 2008.
34. Lurje G and Lenz HJ: EGFR signaling and drug discovery. Oncology 77: 400-410, 2009.
35. Lurje G, Schiesser M, Claudius A and Schneider PM: Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J Oncol 2010: 392652, 2010.
36. Taubert H, Blumke K, Bilkenroth U, et al: Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. Gynecol Oncol 92: 256-261, 2004.
37. Vona G, Sabile A, Louha M, et al: Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156: 57-63, 2000.
38. Pinzani P, Salvadori B, Simi L, et al: Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 37: 711-718, 2006.
39. Muller V, Alix-Panabieres C and Pantel K: Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 46: 1189-1197, 2010.
40. Deng G, Herrler M, Burgess D, Manna E, Krag D and Burke JF: Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 10: R69, 2008.
41. Balic M, Dandachi N, Hofmann G, et al: Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom 68: 25-30, 2005.
42. Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H and Siewert JR: Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 162: 149-155, 2003.
43. Stott SL, Lee RJ, Nagrath S, et al: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2: 25ra23, 2010.
44. Flores LM, Kindelberger DW, Ligon AH, et al: Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J cancer 102: 1495-1502, 2010.
45. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004.
46. Mostert B, Kraan J, Bolt-de Vries J, et al: Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat: April 9, 2010 (Epub ahead of print).
47. Fehm T, Solomayer EF, Meng S, et al: Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 7: 171-185, 2005.
48. Ring AE, Zabaglo L, Ormerod MG, Smith IE and Dowsett M: Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 92: 906-912, 2005.
49. Katz RL, He W, Khanna A, et al: Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin Cancer Res 16: 3976-3987, 2010.
50. Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377, 2008.
51. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221, 2008.
52. Ntouroupi TG, Ashraf SQ, McGregor SB, et al: Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 99: 789-795, 2008.
53. Leversha MA, Han J, Asgari Z, et al: Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15: 2091-2097, 2009.
54. Wu CH, Lin SR, Yu FJ, et al: Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. Int J Cancer 19: 373-379, 2006.
55. Galanzha EI, Shashkov EV, Spring PM, Suen JY and Zharov VP: In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 69: 7926-7934, 2009.
56. Kojima T, Hashimoto Y, Watanabe Y, et al: A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 119: 3172-3181, 2009.
57. Krivacic RT, Ladanyi A, Curry DN, et al: A rare-cell detector for cancer. Proc Natl Acad Sci USA 101: 10501-10504, 2004.
58. Marrinucci D, Bethel K, Lazar D, et al: Cytomorphology of circulating colorectal tumor cells: a small case series. J Oncol 2010: 861341, 2010.
59. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
60. Vermeulen L, Sprick MR, Kemper K, Stassi G and Medema JP: Cancer stem cells-old concepts, new insights. Cell Death Differ 15: 947-958, 2008.
61. Lin EH, Hassan M, Li Y, et al: Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110: 534-542, 2007.
62. Theodoropoulos PA, Polioudaki H, Agelaki S, et al: Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288: 99-106, 2010.
63. Tanaka F, Yoneda K, Kondo N, et al: Circulating tumor cells as a diagnostic marker in primary lung cancer. Clin Cancer Res 15: 6980-6986, 2009.
64. Budd GT, Cristofanilli M, Ellis MJ, et al: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12: 6403-6409, 2006.
65. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG and Terstappen LW: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65: 713-718, 2005.
66. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20: 3404-3412, 2002.
67. Ignatiadis M, Xenidis N, Perraki M, et al: Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25: 5194-5202, 2007.
68. Allen-Mersh TG, McCullough TK, Patel H, Wharton RQ, Glover C and Jonas SK: Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg 94: 96-105, 2007.
69. Cohen SJ, Punt CJ, Iannotti N, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229, 2009.
70. Halabi S, Small EJ, Hayes DF, Vogelzang NJ and Kantoff PW: Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 21: 490-495, 2003.
71. Payne RE, Yague E, Slade MJ, et al: Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10: 51-57, 2009.
72. Liu Z, Jiang M, Zhao J and Ju H: Circulating tumor cells in perioperative esophageal cancer patients: quantitative assay system and potential clinical utility. Clin Cancer Res 13: 2992-2997, 2007.
73. Yen LC, Yeh YS, Chen CW, et al: Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 15: 4508-4513, 2009.
74. Yang MJ, Chiu HH, Wang HM, et al: Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 17: 624-633, 2010.
75. Larson CJ, Moreno JG, Pienta KJ, et al: Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 62: 46-53, 2004.
76. Gradilone A, Petracca A, Nicolazzo C, et al: Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int 106: 710-715, 2010.
77. Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH and Kim CW: TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung cancer: May 13, 2010 (Epub ahead of print).
78. Barbu V, Bonnand AM, Hillaire S, et al: Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multi-center prospective study. Hepatology 26: 1171-1175, 1997.
79. Bessa X, Pinol V, Castellvi-Bel S, et al: Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann Surg 237: 368-375, 2003.
80. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393-9398, 2004.
81. Meng S, Tripathy D, Shete S, et al: uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103: 17361-17365, 2006.
82. Wulfing P, Borchard J, Buerger H, et al: HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12: 1715-1720, 2006.
83. Pestrin M, Bessi S, Galardi F, et al: Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast cancer Res Treat 118: 523-530, 2009.
84. Slade MJ, Payne R, Riethdorf S, et al: Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer 100: 160-166, 2009.
85. Smith SL and Rajan PS: Imaging of pancreatic adenocarcinoma with emphasis on multidetector CT. Clin Radiol 59: 26-38, 2004.
86. De Giorgi U, Valero V, Rohren E, et al: Circulating tumor cells and [18F] flurodeoxyglucose positron emission tomography/ computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27: 3303-3311, 2009.